Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, No. 167 North Lishi Road, Xicheng District, Beijing, 100037, China.
Department of Cardiology, The Central Hospital of Xinxiang, Xinxiang, Henan Province, China.
BMC Cardiovasc Disord. 2021 Jun 14;21(1):299. doi: 10.1186/s12872-021-02115-1.
Oral antiplatelet therapy is the cornerstone of treatment for acute myocardial infaction (AMI). However, detailed usage data on oral antiplatelet therapy are lacking.
Using data from a nationally representative sample of patients with AMI, the detailed usage of oral antiplatelet therapy was analyzed in 40,202 consecutive eligible patients.
The proportions of patients with AMI taking loading doses of aspirin and P2Y12 inhibitors were relatively low (62.2% and 63.6%, respectively), whereas approximately 90% of patients received maintenance doses of aspirin, P2Y12 inhibitors, and dual antiplatelet therapy. The proportions of patients taking loading doses of aspirin and P2Y12 inhibitors gradually decreased with age. Male sex, an educational level of at least college, an interval from onset to treatment of < 24 h, and primary PCI use were associated with a higher proportion of patients taking a loading dose of antiplatelet therapy, whereas those receiving conservative treatment had a lower rate of antiplatelet use (all P < 0.05). The proportion of patients taking loading doses of aspirin was highest in the western region, and that of patients taking loading doses of P2Y12 inhibitors was highest in the eastern region (P < 0.05). In addition, 76.7% of patients with ST-elevation MI and 91% of patients with non-ST-elevation MI received 300-mg loading dose of clopidogrel.
The proportion of patients with AMI receiving loading doses of aspirin and P2Y12 inhibitors during hospitalization was relatively low, and this rate was affected by many factors, such as age, sex, educational level, region of residence, and the interval from onset to treatment. The underutilization of guideline-based P2Y12 inhibitors was also problematic. Hence, quality improvement initiatives are needed to enhance adherence to guidelines to improve consistent use of oral antiplatelet therapy. Trial registration The Chinese Acute Myocardial Infarction Registry; Trial registration number: ChiCTR-ONC-12002636; Registered 31 October 2012; http://www.chictr.org.cn/showproj.aspx?proj=6916.
口服抗血小板治疗是急性心肌梗死(AMI)治疗的基石。然而,缺乏关于口服抗血小板治疗的详细使用数据。
利用来自全国 AMI 患者代表性样本的数据,对 40202 例连续合格患者的口服抗血小板治疗的详细使用情况进行了分析。
AMI 患者服用负荷剂量阿司匹林和 P2Y12 抑制剂的比例相对较低(分别为 62.2%和 63.6%),而大约 90%的患者接受阿司匹林、P2Y12 抑制剂和双联抗血小板治疗的维持剂量。服用负荷剂量阿司匹林和 P2Y12 抑制剂的患者比例随年龄增长逐渐降低。男性、至少受过大学教育、发病至治疗时间间隔<24 小时以及采用直接经皮冠状动脉介入治疗与服用负荷剂量抗血小板治疗的患者比例较高相关,而接受保守治疗的患者抗血小板治疗使用率较低(均 P<0.05)。西部地区服用负荷剂量阿司匹林的患者比例最高,东部地区服用负荷剂量 P2Y12 抑制剂的患者比例最高(P<0.05)。此外,76.7%的 ST 段抬高型心肌梗死患者和 91%的非 ST 段抬高型心肌梗死患者接受了 300mg 负荷剂量氯吡格雷。
AMI 患者住院期间接受阿司匹林和 P2Y12 抑制剂负荷剂量治疗的比例相对较低,且这一比例受到多种因素的影响,如年龄、性别、教育水平、居住地区域和发病至治疗时间间隔等。基于指南的 P2Y12 抑制剂的使用不足也是一个问题。因此,需要采取质量改进措施来提高对指南的依从性,以改善口服抗血小板治疗的持续使用。
中国急性心肌梗死注册研究;试验注册号:ChiCTR-ONC-12002636;注册日期:2012 年 10 月 31 日;网址:www.chictr.org.cn/showproj.aspx?proj=6916。